Jackson Acquisition Company II(JACS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 37.62 | EPS (ttm) | 0.29 | Insider Own | 20.5% | Shs Outstand | 23.8M | Perf Week | 0.19% |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 22.9M | Perf Month | 0.37% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | - | Inst Own | 83.08% | Short Float | 0.01% | Perf Quarter | 1.31% |
| Income | 0.01B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.07 | Perf Half Y | 2.36% |
| Sales | 0.00B | P/B | 1.3 | EPS next 5Y | - | ROA | 3.51% | Short Interest | 0.00M | Perf YTD | 3.93% |
| Book/sh | 8.34 | P/C | 172.97 | EPS past 3/5Y | - | ROE | 6.89% | 52W High | 0% ($10.83) | Perf Year | 3.93% |
| Cash/sh | 0.06 | P/FCF | - | Sales past 3/5Y | - | ROIC | 3.45% | 52W Low | 4.13% ($10.40) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 72.71% | Gross Margin | - | Volatility(W/M) | 0.04% 0.06% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.02 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.77 | EPS Q/Q | -14.67% | Profit Margin | - | RSI (14) | 56.07 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.77 | Sales Q/Q | - | SMA20 | 0.08% ($10.82) | Beta | -0.01 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | 0.52% ($10.77) | Rel Volume | 8.2 | Prev Close | $10.83 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 2.38% ($10.58) | Avg Volume(3M) | 0.03M | Price | $10.83 |
| IPO | 2025/1/30 | Option/Short | No/Yes | Trades | 26 | Volume | 261,013 | Change | - |
A special purpose acquisition company (SPAC) focused on a healthcare-sector acquisition. It has no operating business of its own and holds the proceeds from its IPO in a trust account while it searches for a merger target, primarily in healthcare services and healthcare technology. The sponsor leverages the operating network of Jackson Healthcare to source potential merger candidates.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded more than usual. That is 820% of its average volume.
Company yardsticks do not fit here, so profitability, valuation and earnings are left out. The other verdicts still apply.
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 83.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #1313 of 1433 in the industry
Based on market cap of $62M.
HFBL#1309 Home Federal Bancorp Inc (Louisiana) $65M PER 10.7 JACS#1313 Jackson Acquisition Company II $62M PER 37.6 
DTCX#1317 Datacentrex Inc $60M PER - 
FAQ
What kind of company is JACS?
JACS belongs to the Financial sector and operates in the Shell Companies industry.
What is the market cap of JACS?
The market cap of JACS is approximately $62M, ranking 4,740 within its sector.
What is the P/E ratio of JACS?
JACS has a P/E ratio of approximately 37.6x, which can be used to assess its valuation relative to the Financial sector average.
What is the 52-week high and low for JACS?
JACS has recorded a 52-week high of $10.83 and a low of $10.40.
